GHRP-2
Also referenced as: Pralmorelin
A synthetic hexapeptide GH secretagogue studied in human endocrine physiology.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Investigational
Not FDA-approved for the research uses discussed; no established clinical enhancement indication.
- Human data
- Limited
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A synthetic hexapeptide GH secretagogue studied in human endocrine physiology.
Not FDA-approved for the research uses discussed; no established clinical enhancement indication.
An acute hormone response is not durable evidence of health, recovery or performance benefit.
Why It's Being Studied
- GH secretion
- Endocrine physiology
Mechanism of Action
Ghrelin-receptor agonism stimulates GH release and can also affect other pituitary and stress hormones.
Ghrelin-receptor agonism stimulates GH release and can also affect other pituitary and stress hormones. An acute hormone response is not durable evidence of health, recovery or performance benefit.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- GH secretion
- Endocrine physiology
- Injectable clinical research
Evidence Summary
Small human studies demonstrate acute GH secretion, not established bodybuilding or anti-aging effectiveness.
Higher tiers carry more weight. Filled tiers have evidence for GHRP-2; tap to read it.
- Small human studies demonstrate acute GH secretion, not established bodybuilding or anti-aging effectiveness.
1 cited sources.
- Clinical trial1
Human clinical evidence
- Small human studies demonstrate acute GH secretion, not established bodybuilding or anti-aging effectiveness.
Reported Adverse Events in Research
- Prolactin, ACTH and cortisol increases and uncertain long-term metabolic safety limit interpretation.
Limitations of Current Evidence
- An acute hormone response is not durable evidence of health, recovery or performance benefit.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| GHRP-2 | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Investigational | FDA Approved for Specific Indication |
| Human data | Limited | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Injectable clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Clinical trial
GHRP-2 — clinical trial